With a rapidly growing team of single-cell biologists, genome engineers and deep learning enthusiasts, backed by top-tier TechBio investors, Neptune Bio aims to efficiently engineer sustainable cell state transitions for complex phenotypes and disease. We combine massively scalable high-content single-cell screening and multimodal large language foundation models to identify the best therapies at scale, no matter the combinatorial complexity. Founded in 2023 by Drs. Rahul Satija, Harm Wessels, Yuhan Hao and Ben Van de Graaf, Neptune Bio is led by an excellent team of lead scientists in single-cell biology and method development, genome engineering, and experienced operations. The science behind these platforms has been published in leading journals including Cell, Nature Biotechnology and Nature Methods.
